Health Care | Pharmaceuticals, Biotechnology & Life Sciences | Biotechnology
NASDAQ | Common Stock
ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients.
The company's clinical portfolio comprises eblasakimab (ASLAN004), a monoclonal antibody that targets the IL-13 receptor a1 subunit which is under Phase 2 developed for the treatment of atopic dermatitis and other immunology indications; and farudodstat (ASLAN003), an orally active, potent inhibitor of human dihydroorotate dehydrogenase currently under Phase 2 clinical trials for the treatment of autoimmune diseases.
It has research collaboration agreement with Zenyaku Kogyo Co., Ltd. for the development and commercialization of eblasakimab in atopic dermatitis and all other indications in Japan.
The company was founded in 2010 and is headquartered in Singapore.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Apr 12, 24 | -0.78 Increased by +39.53% | -0.65 Decreased by -20.00% |
| Jan 10, 24 | -0.78 Increased by +25.00% | -0.65 Decreased by -20.00% |
| Oct 27, 23 | -0.56 Increased by +30.00% | -0.78 Increased by +28.21% |
| Aug 11, 23 | -0.11 Increased by +88.42% | -0.80 Increased by +86.25% |
| Apr 28, 23 | -1.29 Decreased by -35.79% | -4.05 Increased by +68.15% |
| Mar 24, 23 | -1.04 Decreased by -30.00% | -0.89 Decreased by -16.85% |
| Oct 28, 22 | -0.80 Decreased by -33.33% | -0.95 Increased by +15.79% |
| Aug 12, 22 | -0.95 Decreased by -171.43% | -0.60 Decreased by -58.33% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 24 | 0.00 Decreased by N/A% | -9.92 M Increased by +48.10% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 23 | 0.00 Decreased by N/A% | -13.51 M Increased by +6.69% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 23 | 0.00 Decreased by N/A% | -9.71 M Increased by +11.17% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 12.00 M Increased by +N/A% | -9.71 M Increased by +24.69% | Decreased by -80.91% Decreased by N/A% |
| Mar 31, 23 | 0.00 Decreased by N/A% | -19.11 M Decreased by -48.19% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 22 | 0.00 Decreased by N/A% | -14.48 M Decreased by -58.47% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 22 | 0.00 Decreased by N/A% | -10.93 M Decreased by -27.77% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 22 | 0.00 Decreased by N/A% | -12.89 M Decreased by -137.46% | Decreased by N/A% Decreased by N/A% |